Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2013 by Abramson Cancer Center of the University of Pennsylvania.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania Identifier:
First received: March 6, 2012
Last updated: February 25, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2015
  Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)